tiprankstipranks
AN2 Therapeutics, Inc. (ANTX)
NASDAQ:ANTX
US Market
Holding ANTX?
Track your performance easily

AN2 Therapeutics, Inc. (ANTX) Income Statement

92 Followers

AN2 Therapeutics, Inc. Income Statement

Last quarter (Q3 2024), AN2 Therapeutics, Inc.'s total revenue was $―, a decrease of ― from the same quarter last year. In Q3, AN2 Therapeutics, Inc.'s net income was $-12.75M. See AN2 Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
---$ 0.00$ 0.00
Cost of Revenue
-----
Gross Profit
-----
Operating Expense
$ 67.00M$ 69.64M$ -42.26M$ 21.57M$ 7.28M
Operating Income
$ -67.00M$ -69.64M$ -42.26M$ -21.57M$ -7.28M
Net Non Operating Interest Income Expense
--$ 1.35M$ 69.00K$ 3.00K
Other Income Expense
$ -6.31M$ -4.90M$ 45.00K$ -38.00K$ -6.32M
Pretax Income
$ -60.70M$ -64.73M$ -40.96M$ -21.54M$ -13.60M
Tax Provision
$ -4.92M$ -4.92M$ -295.00K--
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -60.70M$ -64.73M$ -42.78M$ -21.54M$ -13.60M
Basic EPS
$ -1.96$ -2.74$ -2.79$ -1.53$ -0.97
Diluted EPS
$ -1.96$ -2.74$ -2.79$ -1.53$ -0.97
Basic Average Shares
$ 119.30M$ 23.60M$ 15.34M$ 14.05M$ 14.05M
Diluted Average Shares
$ 119.30M$ 23.60M$ 15.34M$ 14.05M$ 14.05M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 67.00M$ 69.64M$ -42.26M$ 21.57M$ 7.28M
Net Income From Continuing And Discontinued Operation
$ -60.70M$ -64.73M$ -40.96M$ -21.54M$ -13.60M
Normalized Income
$ -24.67M--$ -21.54M$ -13.60M
Interest Expense
-----
EBIT
$ -64.29M$ -69.64M$ -40.96M$ -21.57M$ -7.28M
EBITDA
$ -64.29M$ -69.64M$ -41.65M$ -21.57M$ -7.28M
Currency in USD

AN2 Therapeutics, Inc. Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis